| Antibody-drug conjugates for the treatment of non–hodgkin's lymphoma: target and linker-drug selection AG Polson, J Calemine-Fenaux, P Chan, W Chang, E Christensen, ... Cancer research 69 (6), 2358-2364, 2009 | 306 | 2009 |
| Antibody-based targeting of FGFR3 in bladder carcinoma and t (4; 14)-positive multiple myeloma in mice J Qing, X Du, Y Chen, P Chan, H Li, P Wu, S Marsters, S Stawicki, J Tien, ... The Journal of clinical investigation 119 (5), 1216-1229, 2009 | 295 | 2009 |
| Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin AE Fouts, P Chan, JP Stephan, R Vandlen, B Feierbach Journal of virology 86 (13), 7444-7447, 2012 | 240 | 2012 |
| A strategy for risk mitigation of antibodies with fast clearance I Hötzel, FP Theil, LJ Bernstein, S Prabhu, R Deng, L Quintana, J Lutman, ... MAbs 4 (6), 753-760, 2012 | 234 | 2012 |
| Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the Aβ42: Aβ40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer … WJ Meilandt, H Ngu, A Gogineni, G Lalehzadeh, SH Lee, K Srinivasan, ... Journal of Neuroscience 40 (9), 1956-1974, 2020 | 131 | 2020 |
| DCDT2980S, an anti-CD22-monomethyl auristatin E antibody–drug conjugate, is a potential treatment for non-Hodgkin lymphoma D Li, KA Poon, SF Yu, R Dere, MA Go, J Lau, B Zheng, K Elkins, ... Molecular cancer therapeutics 12 (7), 1255-1265, 2013 | 107 | 2013 |
| High CD21 expression inhibits internalization of anti‐CD19 antibodies and cytotoxicity of an anti‐CD19‐drug conjugate GS Ingle, P Chan, JM Elliott, WS Chang, H Koeppen, JP Stephan, ... British journal of haematology 140 (1), 46-58, 2008 | 87 | 2008 |
| Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination JP Stephan, P Chan, C Lee, C Nelson, JM Elliott, C Bechtel, H Raab, ... Bioconjugate chemistry 19 (8), 1673-1683, 2008 | 85 | 2008 |
| The immunoglobulin superfamily receptome defines cancer-relevant networks associated with clinical outcome E Verschueren, B Husain, K Yuen, Y Sun, S Paduchuri, Y Senbabaoglu, ... Cell 182 (2), 329-344. e19, 2020 | 67 | 2020 |
| A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3/CD276 and PVR/CD155 B Husain, SR Ramani, E Chiang, I Lehoux, S Paduchuri, TA Arena, ... Molecular & Cellular Proteomics 18 (11), 2310-2323, 2019 | 62 | 2019 |
| A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection MR Auerbach, D Yan, R Vij, JA Hongo, G Nakamura, JM Vernes, ... PLoS pathogens 10 (4), e1004060, 2014 | 50 | 2014 |
| Widespread brain distribution and activity following icv infusion of anti‐β‐secretase (BACE1) in nonhuman primates DB Yadav, JA Maloney, KR Wildsmith, RN Fuji, WJ Meilandt, H Solanoy, ... British journal of pharmacology 174 (22), 4173-4185, 2017 | 43 | 2017 |
| Total antibody quantification for MMAE-conjugated antibody–drug conjugates: impact of assay format and reagents KR Kozak, SP Tsai, A Fourie-O’Donohue, J dela Cruz Chuh, L Roth, ... Bioconjugate chemistry 24 (5), 772-779, 2013 | 32 | 2013 |
| Nucleic acid capture assay, a new method for direct quantitation of nucleic acids SP Tsai, A Wong, E Mai, P Chan, G Mausisa, M Vasser, P Jhurani, ... Nucleic Acids Research 31 (6), e25-e25, 2003 | 20 | 2003 |
| Translational approaches for brain delivery of biologics via cerebrospinal fluid SS Sadekar, M Bowen, H Cai, S Jamalian, H Rafidi, W Shatz‐Binder, ... Clinical Pharmacology & Therapeutics 111 (4), 826-834, 2022 | 18 | 2022 |
| Taming hyperactive h DN ase I: Stable inducible expression of a hyperactive salt‐and actin‐resistant variant of human deoxyribonuclease I in CHO cells C Lam, L Santell, B Wilson, M Yim, S Louie, D Tang, D Shaw, P Chan, ... Biotechnology Progress 33 (2), 523-533, 2017 | 17 | 2017 |
| Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response J Dela Cruz Chuh, MA Go, Y Chen, J Guo, H Rafidi, D Mandikian, Y Sun, ... Mabs 13 (1), 1862452, 2021 | 10 | 2021 |
| High throughput screening identifies novel, cell cycle‐arresting small molecule enhancers of transient protein expression HJ Meyer, R Turincio, S Ng, J Li, B Wilson, P Chan, M Zak, D Reilly, ... Biotechnology Progress 33 (6), 1579-1588, 2017 | 9 | 2017 |
| Systematic discovery of Neoepitope–HLA pairs for neoantigens shared among patients and tumor types HR Gurung, AJ Heidersbach, M Darwish, PPF Chan, J Li, M Beresini, ... Nature Biotechnology, 1-11, 2023 | 7 | 2023 |
| Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, a novel anti-BCMA/CD16A bispecific tetravalent antibody for the treatment of multiple myeloma H Cai, S Kakiuchi-Kiyota, R Hendricks, S Zhong, L Liu, AO Adedeji, ... The AAPS Journal 24 (6), 100, 2022 | 7 | 2022 |
